Publication details
CLINICAL IMPLICATION OF HYPERDIPLOIDY/NON-HYPERDIPLOIDY IN MM PATIENTS TREATED BY NEWER DRUGS
| Authors | |
|---|---|
| Year of publication | 2009 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | |
| Description | Multiple myeloma (MM) is a haematological disease characterised by accumulation of changed clone of plasma cells (myeloma cells) in bone marrow. This disorder is currently incurable and therefore there is a need for searching new prognostic factors, which are suitable for treatment optimalization. Among the most significant factors in multiple myeloma diagnosis belong cytogenetic changes. The main aim of this work was investigation of bone marrow samples from 74 MM patients treated by new drugs (Velcade/Thalidomid) for presence of hyperdiploidy / non-hyperdiploidy. Partial aims were focused on both comparison of incidence another prognostic important chromosomal MM abnormalities (translocation t(4;14); deletion 13q14, deletion 17p13 and gain/amplification 1q21) between hyperdiploid and non-hyperdiploid group of patients and comparison of impact of hyperdiploidy / non-hyperdiploidy on disease prognosis using survival analyses of both groups of patients. |
| Related projects: |